Abstracts tagged "rheumatoid arthritis"

Abstract Number: 89 • 2019 ACR/ARP Annual Meeting
Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis
Ximei Zhang¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State College of Medicine, Columbus, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Enhanced evidence supports that autoimmune diseases often result from an imbalance between regulatory T cells (Tregs) and interleukin-17-producing T helper (Th17) cells. However, under…
Abstract Number: 522 • 2019 ACR/ARP Annual Meeting
Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis
Thierry Sornasse¹, Jeremy Sokolove ¹ and Iain McInnes ², ¹AbbVie Immunology Clinical Development, Redwood City, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) with an inadequate response (IR) to…
Abstract Number: 980 • 2019 ACR/ARP Annual Meeting
Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis
Ana Igea ¹, Tiago Carvalheiro ², Beatriz Malvar Fernandez ², Angela Rodriguez-Trillo ³, Trudy McGarry ⁴, Carmen Conde ⁵, Douglas Veale ⁶, Ursula Fearon ⁷, Africa Gonzalez ¹, Timothy R.D. Radstake ⁸, Kris A. Reedquist ² and Samuel Garcia⁹, ¹Department of Immunology, Centro de Investigaciones Biomédicas (CINBIO), Centro de Investigación Singular de Galicia, Instituto de Investigación Sanitaria Galicia Sur, Universidad de Vigo, Vigo, Spain, ²Department of Rheumatology and Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands, ³laboratorio de Reumatología Experimental y Observacional, Instituto de Investigación Sanitaria de Santiago (IDIS)-Hospital Clinico (CHUS), Santiago de Compostela, Spain, ⁴Department of Molecular Rheumatology, Trinity Biomedical Science Institute, Trinity College Dublin, Dublin, Ireland, ⁵Laboratorio de Reumatología Experimental y Observacional, y Servicio de Reumatología, Instituto de Investigacion Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain, ⁶EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland, ⁷Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, ⁸Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, ⁹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, Spain
Background/Purpose: The semaphorin family is a large group of proteins initially described in axon guidance. However, semaphorins also play a role in other processes involved…
Abstract Number: 1365 • 2019 ACR/ARP Annual Meeting
Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
Clifton Bingham¹, Shelly Kafka ², Shawn Black ³, Stephen Xu ⁴ and Jeffrey Curtis ⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, RI, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Use of PROs to assess health-related quality of life in clinical practice, research studies, and clinical trials in Rheumatoid Arthritis (RA) remains an ongoing…
Abstract Number: 1945 • 2019 ACR/ARP Annual Meeting
Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients
Ankita Singh¹, Harikrishnan Nair ², Vikas Gupta ², Pradeepta Sekhar ², Ramnath Misra ³ and Amita Aggarwal ⁴, ¹Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Methotrexate (MTX) is first line therapy to treat rheumatoid arthritis (RA) patients. However, the response is variable with 50-60% showing response and this variability…
Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez ¹, Naydi Pérez-Ríos ¹, Noelia Rodríguez ¹, Grissel Ríos ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…
Abstract Number: 2875 • 2019 ACR/ARP Annual Meeting
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Mark Genovese¹, Kenneth Kalunian ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, YingMeei Tan ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Anemia, thrombocytopenia and leukopenia in RA patients treated with non-Janus Kinase 1 (JAK1) selective inhibitors may be due to inhibition of hematopoietic growth factors…
Abstract Number: 100 • 2019 ACR/ARP Annual Meeting
Targeting ITK Signaling Ameliorates Collagen-Induced Arthritis via Shifting the Balance Between Th17 and Regulatory Th17 Cells
Ye Chen¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State University, Columbus, OH, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that cannot be cured and current approaches have some severe side effects. Although the pathogenesis is…
Abstract Number: 524 • 2019 ACR/ARP Annual Meeting
A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies
Joel Kremer¹, Filip Van den Bosch ², Andrea Rubbert-Roth ³, Sebastiao Radominski ⁴, Gerd Burmester ⁵, Heidi Camp ⁶, Sebastian Meerwein ⁷, Mark Howard ⁸, Yanna Song ⁹, Sheng Zhong ¹⁰ and Bernard Combe ¹¹, ¹Albany Medical College, Albany, NY, ²Ghent University Hospital, Ghent, Belgium, ³Kantonsspital St. Gallen, St Gallen, Switzerland, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Charité—University Medicine Berlin, Berlin, Germany, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Inc., North Chicago, IL, USA, North Chicago, ¹⁰AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ¹¹CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Upadacitinib (UPA), a selective JAK1 inhibitor, has shown efficacy in patients with rheumatoid arthritis (RA) when combined with methotrexate (MTX) or other conventional synthetic…
Abstract Number: 981 • 2019 ACR/ARP Annual Meeting
Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models
Hani Manfred Sauermilch¹, Marie-Lisa Hülser ¹, Carina Schreiyäck ¹, Yubin Luo ², Aline Bozec ², Georg Schett ³, Ulf Müller-Ladner ⁴ and Elena Neumann ⁵, ¹Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Giessen, Germany, ²Department Clinic of Medicine 3 - Immunology and Rheumatology, University of Erlangen-Nürnberg, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁴Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Gießen, Hessen, Germany, ⁵Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, Giessen, Hessen, Germany
Background/Purpose: Adipocytokines are bioactive factors mainly produced by adipose tissue and exert many important effects on energy homeostasis as well as immune responses. Osteoarthritis (OA)…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
Abstract Number: 1966 • 2019 ACR/ARP Annual Meeting
A Genome-Wide Association Study of Copy Number Variations Identifies the Deletion Associated with Efficacy of TNF-Alpha Blocker Therapy in Korean Patients with Rheumatoid Arthritis
Ki-Nam Gu ¹, So-Young Bang², Hye-Soon Lee ³, Youngho Park ², Juyeon Kang ², Ji-Soong Kim ², Bora Nam ², Hyun-Seung Yoo ⁴, Jung-Min Shin ², Yeon-Kyung Lee ², Tae-Han Lee ², Sehwan Chun ¹, Soo-Kyung Cho ², Chan-Bum Choi ², Yoon-Kyoung Sung ⁵, Tae-Hwan Kim ², Jae-Bum Jun ², DaeHyun Yoo ², Kwangwoo Kim ¹ and Sang-Cheol Bae ², ¹Kyung Hee University, Seoul, Republic of Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Department of Internal Medicine, Hanyang University Guri Hospital,Hanyang University School of Medicine, Guri, Korea, Guri, Republic of Korea, ⁴Hanyang University Hospital, Guri, Republic of Korea, ⁵Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Copy number variation (CNV) is the most common structural variation defined as large ( >1 kb) genomic deletions and duplications and could yield a…
Abstract Number: 2370 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
pia Lois¹, Zulema Rosales Rosado ¹, Judit Font Urgelles ², Cristina Vadillo Font ¹, isabel Hernandez Rodriguez ¹, Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades in strategies, objectives and therapeutic options, especially with the…
Abstract Number: 101 • 2019 ACR/ARP Annual Meeting
CD126 Negative CD4+Foxp3+ Cell Represents a Superior Treg Subset in Treating Autoimmune Diseases
Ye Chen¹, Julie Wang ², Nancy Olsen ³, Wael Jarjour ⁴ and Song Guo Zheng ⁴, ¹Ohio State University, Columbus, OH, ²Ohio State University, columbus, ³Penn State University, Hershey, PA, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Regulatory T (Treg) cells play an important role in maintaining immunologic homeostasis. Abnormal Treg cells were found in some autoimmune diseases. Transferred natural Treg…
Abstract Number: 527 • 2019 ACR/ARP Annual Meeting
Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Roy Fleischmann¹, Jose Jeffrey Enejosa ², In-Ho Song ³, Eduardo Mysler ⁴, Louis Bessette ⁵, Charles Peterfy ⁶, Patrick Durez ⁷, Andrew Östör ⁸, Yijie Zhou ⁹ and Mark Genovese ¹⁰, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁴Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁵Laval University, Quebec City, QC, Canada, ⁶Spire Sciences Inc, Boca Raton, ⁷Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, UCL Saint-Luc, Brussels, Belgium, ⁸Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ⁹AbbVie Inc., North Chicago, ¹⁰Stanford University, Stanford, CA
Background/Purpose: In the SELECT-COMPARE study in rheumatoid arthritis (RA) patients (pts) with inadequate response to methotrexate (MTX), upadacitinib (UPA), a JAK1- selective inhibitor, was superior…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].